Tag Archives: PIT

Photoimmunotechnology as a powerful biological tool for molecular-based elimination of target cells and microbes, including bacteria, fungi and viruses

October 4, 2023 by Modulight Content
No comments
Published in: Nature Protocols Authors: Tadayuki Iwase, Kimihiro Ito, Takashi Nishimura, Kei Miyakawa, Akihide Ryo, Hisataka Kobayashi, Makoto Mitsunaga The Jikei University School of Medicine  Published in: Nature Protocols Authors: Tadayuki Iwase, Kimihiro Ito, Takashi Nishimura, Kei Miyakawa, Akihide Ryo, Hisataka Kobayashi, Makoto Mitsunaga The Jikei University School of Medicine Microbial pathogens, including bacteria, fungi and viruses, can develop resistance to clinically used drugs; therefore, finding new therapeutic agents is an ongoing challenge. Recently, we reported the photoimmuno-antimicrobial strategy (PIAS), a type of photoimmunotechnology, that enables molecularly targeted elimination of a wide range of microbes, including the viral pathogen severe acute respiratory syndrome coronavirus 2 and the multidrug-resistant bacterial pathogen Continue reading →

Fluorescence-guided photoimmunotherapy using targeted nanotechnology and ML7710 to manage peritoneal carcinomatosis

September 6, 2023 by Modulight Content
No comments
Published in: Science Advances Authors: Barry J. Liang(1,2), Sumiao Pang(1), Robert Perttilä(3), Chen-Hua Ma(1), Payal Srivastava(1), Brandon Gaitan(1), Aaron J. Sorrin (1), Nada Fadul(1), Zoe Ylöniemi(3), Dana M. Roque(4,5), Tayyaba Hasan(6), Petteri Uusimaa(3), Huang-Chiao Huang(1,4*) (1) Fischell Department of Bioengineering, University of Maryland (2) Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health (3) Modulight Corp., Finland (4) Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine (5) Department of Obstetrics, Gynecology and Reproductive Sciences, University Continue reading →Published in: Science Advances Authors: Barry J. Liang(1,2), Sumiao Pang(1), Robert Perttilä(3), Chen-Hua Ma(1), Payal Srivastava(1), Brandon Gaitan(1), Aaron J. Sorrin (1), Nada Fadul(1), Zoe Ylöniemi(3), Dana M. Roque(4,5), Tayyaba Hasan(6), Petteri Uusimaa(3), Huang-Chiao Huang(1,4*) (1) Fischell Department of Bioengineering, University of Maryland (2) Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health (3) Modulight Corp., Finland (4) Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine (5) Department of Obstetrics, Gynecology and Reproductive Sciences, University Continue reading →

Towards Photodynamic Image-Guided Surgery of Head and Neck Tumors: Photodynamic Priming Improves Delivery and Diagnostic Accuracy of Cetuximab-IRDye800CW

June 28, 2022 by Modulight
No comments
Published in: Frontiers in Oncology Authors: Chanda Bhandari, John Fakhry, Menitte Eroy, Jane Junghwa Song, Kimberley Samkoe, Tayyaba Hasan, Kenneth Hoyt, Girgis Obaid    Published in: Frontiers in Oncology Authors: Chanda Bhandari, John Fakhry, Menitte Eroy, Jane Junghwa Song, Kimberley Samkoe, Tayyaba Hasan, Kenneth Hoyt, Girgis Obaid   The study showed that photodynamic priming (subtherapeutic doses of light using ML6500) of tumor microenvironment with nanoliposomal BPD is highly beneficial for delivery of antibodies (Cet-IR800) to H&N tumor in mice. Priming significantly improved the tumor accumulation of Cet-IR800 and diagnostic accuracy of tumor detection, as monitored with fluroescence imaging.   Read the article here

Antitumor Effect and Induced Immune Response Following Exposure of Hexaminolevulinate and Blue Light in Combination with Checkpoint Inhibitor in an Orthotopic Model of Rat Bladder Cancer

February 25, 2022 by Modulight
No comments
Published in: Biomedicines Authors: Laureline Lamy, Jacques Thomas, Agnès Leroux, Jean-François Bisson, Kari Myren, Aslak Godal, Gry Stensrud, Lina Bezdetnaya    Published in: Biomedicines Authors: Laureline Lamy, Jacques Thomas, Agnès Leroux, Jean-François Bisson, Kari Myren, Aslak Godal, Gry Stensrud, Lina Bezdetnaya   Blue light cystoscopy/Photodynamic diagnosis (PDD) was shown in rat models of bladder cancer to not only help in visualization and better removal of tumors, but also lead to anti-tumor effects and stimulation of immune system. ML6500 was used as blue light source for PDD.   Read the article here

CD29 targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of a pigmented melanoma model

January 4, 2022 by Modulight
No comments
Published in: OncoImmunology Authors: Aki Furusawa, Ryuhei Okada, Fuyuki Inagaki, Hiroaki Wakiyama, Takuya Kato, Hideyuki Furumoto, Hiroshi Fukushima, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi    Published in: OncoImmunology Authors: Aki Furusawa, Ryuhei Okada, Fuyuki Inagaki, Hiroaki Wakiyama, Takuya Kato, Hideyuki Furumoto, Hiroshi Fukushima, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi   The study aimed to develop photoimmunotherapy for pigmented melanoma, which can challenging indication since the pigment could absorb light and make treatment ineffective. In vitro & in vivo studies with ML7710 laser compared PIT against pigmented and non-pigmented melanoma and found no differences. CD29 targeted PIT was more effective than CD44 targeted PIT, relating to expression of CD44 on Continue reading →

Light penetration depth in brain with different photosensitizers

October 28, 2021 by Modulight Content
No comments
  Motivation for the study Glioblastoma is the most aggressive and lethal brain cancer with an average prognosis of 15 months. Fluorescence-guided surgery (FGS) for glioblastoma was FDA-approved in 2017, while photodynamic therapy (PDT) remains an active area of clinical investigation with very promising results so far. The aim of PDT is to eradicate the invasive cancer cells within 2 cm of the resected area where the glioblastoma most often recurs. However, a significant hurdle of this therapy modality is the limited light penetration depth Continue reading →Customer case Research by: University of Maryland, Optical Therapeutics & Nanotechnology Laboratory led by Prof. Huang. Research focuses on precision cancer nanomedicine, drug delivery strategies, overcoming cancer resistance, mechanism-based combination therapies, site-directed photochemistry and fluorescence diagnostics. Modulight has started a joint R&D program with Dr. Huang lab to study novel EGFR-targeted combination therapy/diagnostic agent PIC-Nal-IRI developed by Huang lab. Modulight products: ML6600 laser system (635 nm and 689 nm). Professor Huang-Chiao Huang Laser use: Targeted photodynamic therapy/photoimmunotherapy with benzoporphyrin derivative (BPD) & 5-aminolevulinic acid (5-ALA) photosensitizers. Continue reading →

Combining photoimmunotherapy with immune checkpoint inhibition

July 14, 2021 by Modulight Content
No comments
Motivation for the study The motivation was to study if photoimmunotherapy could enhance anti-tumor immunity when combined with immune checkpoint inhibition. CD44-targeted photoimmunotherapy was applied against poorly immunogenic, “cold” tumor and antitumor effect was studied alone and in combination with anti-PD-1 immune checkpoint inhibition. Sensitization of this “cold” tumor to immune checkpoint inhibition after photoimmunotherapy would mean that the tumor has been converted into highly immunogenic, “hot” tumor infiltrated with killer T cells mainly responsible for eradicating the tumor. The formation of immunological antitumor memory Continue reading →Customer case The Laboratory of Molecular Theranostics at National Cancer Institute (NCI) is a major research section of the Molecular Imaging Program at National Cancer Institute (NCI) and is led by Dr. Hisataka Kobayashi who is the father of photoimmunotherapy. The ground-breaking research includes the development of imaging and theranostic probes with a particular emphasis on optical probes, which can aid in cancer detection during cancer resection or endoscopy. Dr. Hisataka Kobayashi M.D., PhD Dr. Peter L. Choyke M.D., PhD   Modulight products: ML7710 (multiple channels Continue reading →